The Immunotherapy Turn in Small Cell Lung Cancer

An interactive, clinician-facing chronicle of the trials that reshaped small cell lung cancer — from the platinum–etoposide backbone and second-line topoisomerase-I inhibitors through the plateau decades, into the PD-L1 checkpoint era of the extensive-stage frontline, and the arrival of DLL3 T-cell engagers. Click any drug to trace its Phase 1→3→approval lineage; click a trial for arms, endpoints, results, and FDA/EMA milestones.